Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers

The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. While this model is useful to most practicing clinicians, the treatment outcome of individual patient is not certain at the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Christopher Y.C., Lie, Erich Ferdiansyah, Wu, Cheng-Hsun, Chow, Louis W.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659858/
https://www.ncbi.nlm.nih.gov/pubmed/36387174
http://dx.doi.org/10.3389/fonc.2022.964824
_version_ 1784830292752596992
author Chow, Christopher Y.C.
Lie, Erich Ferdiansyah
Wu, Cheng-Hsun
Chow, Louis W.C.
author_facet Chow, Christopher Y.C.
Lie, Erich Ferdiansyah
Wu, Cheng-Hsun
Chow, Louis W.C.
author_sort Chow, Christopher Y.C.
collection PubMed
description The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. While this model is useful to most practicing clinicians, the treatment outcome of individual patient is not certain at the start of treatment. As the understanding of the translational research of carcinogenesis and the related changes in cancer genetics and tumor microenvironment during treatment is critical in the selection of right choice of treatment to maximize the successful clinical outcome for the patient, this review article intends to discuss the latest developments in the genetic and molecular mechanisms of cancer progression and treatment resistance, and how they influence the planning of the treatment strategies of HER2-positive breast cancers.
format Online
Article
Text
id pubmed-9659858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96598582022-11-15 Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers Chow, Christopher Y.C. Lie, Erich Ferdiansyah Wu, Cheng-Hsun Chow, Louis W.C. Front Oncol Oncology The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. While this model is useful to most practicing clinicians, the treatment outcome of individual patient is not certain at the start of treatment. As the understanding of the translational research of carcinogenesis and the related changes in cancer genetics and tumor microenvironment during treatment is critical in the selection of right choice of treatment to maximize the successful clinical outcome for the patient, this review article intends to discuss the latest developments in the genetic and molecular mechanisms of cancer progression and treatment resistance, and how they influence the planning of the treatment strategies of HER2-positive breast cancers. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9659858/ /pubmed/36387174 http://dx.doi.org/10.3389/fonc.2022.964824 Text en Copyright © 2022 Chow, Lie, Wu and Chow https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chow, Christopher Y.C.
Lie, Erich Ferdiansyah
Wu, Cheng-Hsun
Chow, Louis W.C.
Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title_full Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title_fullStr Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title_full_unstemmed Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title_short Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
title_sort clinical implication of genetic composition and molecular mechanism on treatment strategies of her2-positive breast cancers
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659858/
https://www.ncbi.nlm.nih.gov/pubmed/36387174
http://dx.doi.org/10.3389/fonc.2022.964824
work_keys_str_mv AT chowchristopheryc clinicalimplicationofgeneticcompositionandmolecularmechanismontreatmentstrategiesofher2positivebreastcancers
AT lieerichferdiansyah clinicalimplicationofgeneticcompositionandmolecularmechanismontreatmentstrategiesofher2positivebreastcancers
AT wuchenghsun clinicalimplicationofgeneticcompositionandmolecularmechanismontreatmentstrategiesofher2positivebreastcancers
AT chowlouiswc clinicalimplicationofgeneticcompositionandmolecularmechanismontreatmentstrategiesofher2positivebreastcancers

Ejemplares similares